HemoShear LLC obtained both substantial financial backing and validation of its technology platform on Oct. 17 through a collaboration with Takeda Pharmaceutical Co. Ltd. to identify novel targets for non-alcoholic steatohepatitis (NASH).
The deal in a big liver disease indication is an important endorsement for HemoShear's REVEAL-tx disease-modeling platform, which the Charlottesville, Va.-based company created based on a goal to develop better bench research tools than cells in petri dishes or animal models
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?